Stay updated on Pembrolizumab & Gemcitabine in Leiomyosarcoma Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab & Gemcitabine in Leiomyosarcoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab & Gemcitabine in Leiomyosarcoma Clinical Trial page

  1. Check
    4 days ago
    No Change Detected
  2. Check
    11 days ago
    Change Detected
    Summary
    Version updated from v3.4.3 to v3.5.0 on the page, indicating a platform-level update without changes to study data or content.
    Difference
    0.1%
    Check dated 2026-03-18T16:59:14.000Z thumbnail image
  3. Check
    18 days ago
    Change Detected
    Summary
    Revision: v3.4.3 was added, replacing the previous v3.4.2 in the revision history.
    Difference
    0.1%
    Check dated 2026-03-11T16:39:40.000Z thumbnail image
  4. Check
    25 days ago
    No Change Detected
  5. Check
    39 days ago
    Change Detected
    Summary
    Results section updated with data on dose-limiting toxicities, timing, and RECIST responses. Exploratory biomarker endpoints were removed.
    Difference
    3%
    Check dated 2026-02-18T04:24:21.000Z thumbnail image
  6. Check
    46 days ago
    Change Detected
    Summary
    Added Revision: v3.4.2 and removed Revision: v3.4.1 along with the funding/operating-status notice. There are no visible changes to the study details or results.
    Difference
    0.5%
    Check dated 2026-02-11T02:32:19.000Z thumbnail image
  7. Check
    53 days ago
    Change Detected
    Summary
    Administrative notices were added: a government funding lapse notice and an update to version 3.4.1. The prior version 3.4.0 was removed.
    Difference
    0.5%
    Check dated 2026-02-03T23:25:13.000Z thumbnail image
  8. Check
    60 days ago
    Change Detected
    Summary
    Added a glossary toggle and updated footer/version details to show 'Last Update Submitted that Met QC Criteria' and Revision: v3.4.0. Removed older wording/capitalization variants ('Last Update Submitted that met QC Criteria', 'No FEAR Act data') and the previous revision label (v3.3.4).
    Difference
    0.2%
    Check dated 2026-01-28T00:17:16.000Z thumbnail image

Stay in the know with updates to Pembrolizumab & Gemcitabine in Leiomyosarcoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Gemcitabine in Leiomyosarcoma Clinical Trial page.